Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection

Journal of Clinical Virology

Volumn 19, Issue 1-2, 2000, Pages 7-23

  Dillner, Joakim ^a,b  

^a UNIVERSITY OF TAMPERE   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical neoplasia; HPV infection; Human papillomavirus infection

Indexed keywords

VIRUS VACCINE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; COMPARATIVE STUDY; DISEASE TRANSMISSION; FEMALE; HUMAN; INFECTION PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR; VIRUS INFECTION;

AGE FACTORS; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; FINLAND; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POPULATION DYNAMICS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEXUALLY TRANSMITTED DISEASES; SMOKING; TIME FACTORS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0033737629     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(00)00126-8     Document Type: Article

References (76)

1. Stablity over time of human papillomavirus type 16 antibody levels
2. Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989
3. A survey of seroprevalences of human papillomavirus types 16, 18 and 33 among children
4. No serological evidence for non-sexual spread of HPV 16
5. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study
6. Effect of organized screening on cervical cancer incidence and mortality in Finland 1963-1995: Recent increase in cervical cancer incidence
7. Immune responses against human papillomavirus type 16 (HPV16) virus-like particles in a cohort study of women with cervical intraepithelial neoplasia: Systemic but not local IgA responses correlate with clearance of HPV16
8. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women
9. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
10. Surface conformational and linear epitopes on HPV16 and HPV18 virus-like particles as defined by monoclonal antibodies
11. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6
12. A prospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears
13. Topografical and conformational epitopes of bovine papillomavirus type 1 defined by monoclonal antibodies
14. Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine and avian papillomaviruses
15. The serological response to papillomaviruses
16. A population-based seroepidemiological study of cervical cancer
17. Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior
18. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer
19. Seroepidemiological association between human papillomavirus infection and risk of prostate cancer
20. High risk genital papillomavirus infections are not spread vertically
21. Human papillomavirus infection is transient in young women: A population-based cohort study
22. A colposcopic case-control study of cervical squamous intraepithelial lesions in women with anogenital warts
23. The sexually transmitted disease model for cervical cancer: Incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection
24. Transmission of cervical human papillomavirus infection by sexual activity: Differences between low and high oncogenic risk types
25. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
26. Association of serum IgG antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma
27. Determinants of genital human papillomavirus infection in low-income women in Washington, DC
28. Persistence of type-specific human papillomavirus infection among cytologically normal women
29. Natural history of cervicovaginal papillomavirus infection in young women
30. Effect of screening for cancer in the Nordic countries on deaths, costs and quality of life up to the year 2017
31. Reliable high risk HPV DNA testing by polymerase chain reaction: An intermethod and intramethod comparison
32. Immunologic relatedness of papillomaviruses from different species
33. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific
34. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: A population-based cohort study
35. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for post-natal HPV16 vaccination
36. A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16
37. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark) - A second look
38. Sexual behavior and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study
39. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intraepithelial neoplasia, in relation to human papillomavirus infection
40. Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein
41. Serological evidence of an association of past Chlamydia trachomatis infection with invasive cervical carcinoma
42. Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16
43. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma
44. Vaccination against colonising bacteria with multiple serotypes
45. No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11
46. Detection of human papillomavirus type 16 DNA and of antibodies to human papillomavirus type 16 proteins in children
47. Serologic response to human papillomavirus type 16 virus-like particles in HPV 16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain
48. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer in high-risk populations
49. A population-based case-control study of human papillomavirus type 16 seropositivity and incident high-grade dysplasia of the uterine cervix
50. Seropositivity against HPV16 capsids: A better marker of past sexual behavior than presence of HPV DNA
51. Combined effect of smoking and human papillomavirus infection in cervical carcinogenesis
52. The impact of screening on the incidence of cervical cancer in England and Wales 1963-1978
53. Has screening for cervical cancer been successful
54. Risk factors for genital papillomavirus infection in populations at high and low risk for cervical cancer
55. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
56. Papillomavirus is resistant to desiccation
57. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix
58. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis
59. Correlates of spread of human papillomavirus infection
60. Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays
61. Effect of smoking cessation on cervical lesion size
62. Hepatocellular carcinoma and the hepatitis B virus: Evidence for a causal association
63. Type-specific persistence of human papillomavirus before invasive cervical cancer
64. Cervical mucus antibodies to HPV in relation to the presence of viral DNA
65. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera
66. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids
67. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia
68. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV16 DNA-positive and negative women
69. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma
70. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women
71. Identification of human papillomavirus seroconversions
72. A prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection
73. Adami HO Smoking and oral contraceptives as risk factors for cervical carcinoma in situ